RAD51 and ovarian carcinoma: The most notable example is the independent validation of treatment-induced nuclear Rad51 foci as a functional marker of homologous recombination (HR) within clinical samples of breast and ovarian cancer and its ability to predict patient response to PARP inhibitors and platinum drugs [47,48,49,50,51,52,53].